---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096165"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:22.182529+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reports Q2 2024 net loss $21.5M; stops KZR-261 Phase 1, revises PORTOLA data to H1 2025

## Summary
- Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).
- Enrollment completed in PORTOLA Phase 2a for autoimmune hepatitis; topline data expected first half 2025 (revised from prior guidance).
- Enrollment stopped in KZR-261 Phase 1 for refractory solid tumors; no objective responses observed, resources redirected to zetomipzomib.
- PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
- R&D expenses down $4.7M to $16.3M vs $21.0M; restructuring charge $1.5M related to office space impairment.

## SEC filing metadata
- accession: 0000950170-24-096165
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/0000950170-24-096165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/kzr-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096165
- JSON: https://secwatch.observer/filing/0000950170-24-096165.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.